AAN 2021 | Upcoming treatments for migraine: zavegepant, rimegepant and atogepant
The outlook for migraine treatment is exciting, with many new therapies under investigation. Jessica Ailani, MD, FAAN, Medstar Georgetown University Hospital, Washington, DC, discusses the current approvals for the treatment of migraine and promising novel medications in the pipeline. At present, several CGRP monoclonal antibodies are approved for migraine prevention, and two gepants are available for acute migraine treatment. Zavegepant is a third-generation selective small molecule CGRP receptor antagonist that has recently completed a Phase II trial (NCT03872453) using intranasal administration for acute migraine treatment. A number of novel gepants are also under investigation in the preventative setting, including rimegepant and atogepant. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.
Disclosures
Consulting: (Honoraria for independent consulting) Amgen, Abbvie, Biohaven, Eli Lilly and Company, Lundbeck, Teva, Impel, Satsuma, Theranica, Axsome, Neso, GlaxoSmithKline, Aeon, Medscape
Ownership of Stocks: CtrM
Speakers Bureau: (Honoraria for promotional speaking) Allergan/Abbvie, Amgen, Biohaven, Eli Lilly and Company, Lundbeck, Teva
Editorial services: (Honoraria) Current Pain and Headache Reports, Section editor, Unusual Headache Syndromes, NeurologyLive, SELF (medical reviewer)
Clinical Trial Grants: (Fees to Institution) American Migraine Foundation, Allergan, Biohaven, Eli Lilly and Company, Satsuma, Zosano
